Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Stock Is Tumbling Today

By Keith Speights - Updated May 12, 2021 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst downgraded the drugmaker.

What happened

Shares of Amarin (AMRN 12.40%) were tumbling 5.5% lower as of 10:40 a.m. EDT on Wednesday after falling as much as 7.2% earlier in the session. The decline came after Goldman Sachs downgraded the biotech stock from a neutral rating to sell and slashed its price target by $1 to $5 per share.

So what

Investors shouldn't overreact to analysts' downgrades and price-target cuts. However, it's always a good idea to understand the rationale behind them.

In this case, Goldman Sachs analyst Paul Choi thinks that Amarin will experience significant pressure on U.S. Vascepa sales due to generic competition. Choi's view was based on conversations with physicians in the U.S.

Man wearing a sportscoat holding his thumb down

Image source: Getty Images.

This isn't a surprising take at all. Amarin itself reported relatively flat sales for Vascepa in the first quarter. The drugmaker also said that the introduction of generic rivals in the U.S. "created disruption" to Vascepa's growth. 

Now what

The main thing to watch with Amarin going forward is its rollout of Vascepa in Europe (where the drug will be marketed as Vazkepa). Amarin plans to launch the drug in Germany before the end of the third quarter of this year. It's negotiating pricing in Europe on a country-by-country basis. 

Editor's note: A previous version of this article incorrectly stated that the new Goldman Sachs price target for Amarin was $1 instead of the price target being cut by $1 to $5. The Fool regrets the error.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Corporation plc Stock Quote
Amarin Corporation plc
$1.45 (12.40%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.